Key Points
- Insider purchase: Creo Medical Group insider Richard John Rees bought 6,250 shares on July 1 at GBX 14 each, spending a total of £875.
- Stock performance: The shares were down 2.5% and last traded at GBX 14.38, near the company’s 52-week low of GBX 9.52 and below its 52-week high of GBX 18.50.
- Analyst view and fundamentals: Shore Capital reiterated a "house stock" rating with a GBX 40 price target, while the company reported a small quarterly loss and analysts expect a full-year EPS loss.
Creo Medical Group PLC (LON:CREO - Get Free Report) insider Richard John Rees acquired 6,250 shares of the business's stock in a transaction dated Wednesday, July 1st. The stock was purchased at an average price of GBX 14 per share, for a total transaction of £875.
Creo Medical Group Stock Down 2.5%
Shares of LON:CREO opened at GBX 14.38 on Tuesday. The company has a debt-to-equity ratio of 8.20, a quick ratio of 2.19 and a current ratio of 3.22. Creo Medical Group PLC has a 1 year low of GBX 9.52 and a 1 year high of GBX 18.50. The stock has a market capitalization of £69.83 million, a P/E ratio of 14.38 and a beta of 1.62. The stock has a 50-day simple moving average of GBX 13.22 and a 200-day simple moving average of GBX 12.93.
Creo Medical Group (LON:CREO - Get Free Report) last posted its earnings results on Friday, May 22nd. The company reported GBX (0.04) earnings per share (EPS) for the quarter. The business had revenue of GBX 600 million for the quarter. Creo Medical Group had a return on equity of 9.56% and a net margin of 88.33%. Equities analysts forecast that Creo Medical Group PLC will post -10.0800005 earnings per share for the current year.
Analyst Upgrades and Downgrades
Separately, Shore Capital Group restated a "house stock" rating and set a GBX 40 price objective on shares of Creo Medical Group in a research note on Monday, June 29th.
Check Out Our Latest Stock Report on Creo Medical Group
About Creo Medical Group
(
Get Free Report)
Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
